An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska

被引:116
作者
Baggett, HC
Hennessy, TW
Leman, R
Hamlin, C
Bruden, D
Reasonover, A
Martinez, P
Butler, JC
机构
[1] CDC, Arctic Invest Program, Natl Ctr Infect Dis, Anchorage, AK 99508 USA
[2] CDCP, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA USA
[3] Indian Hlth Serv, Albuquerque, NM USA
[4] Yukon Kuskokwim Hlth Corp, Bethel, AK USA
关键词
D O I
10.1086/502221
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: We investigated a large outbreak of community-onset methicillin-resistant Staphylococcus aureus (MRSA) infections in southwestern Alaska to determine the extent of these infections and whether MRSA isolates were likely community acquired. DESIGN: Retrospective cohort study. SETTING: Rural southwestern Alaska. PATIENTS: All patients with a history of culture-confirmed S.-aureus infection from March 1, 1999, through August 10,2000. RESULTS: More than 86% of culture-confirmed S. aureus infections were methicillin resistant, and 84% of MRSA infections involved skin or soft tissue; invasive disease was rare. Most (77%) of the patients with MRSA skin infections had community-acquired MRSA (no hospitalization, surgery, dialysis, indwelling line or catheter, or admission to a long-term-care facility in the 12 months before infection). Patients with MRSA skin infections were more likely to have received a prescription for an antimicrobial agent in the 180 days before infection than were patients with methicillin-susceptible S. aureus skin infections. CONCLUSIONS: Our findings indicate that the epidemiology of MRSA in rural southwestern Alaska has changed and suggest that the emergence of community-onset MRSA in this region was not related to spread of a hospital organism. Treatment guidelines were developed recommending that beta-lactam antimicrobial agents not be used as a first-line therapy for suspected S. aureus infections.
引用
收藏
页码:397 / 402
页数:6
相关论文
共 29 条
[1]   Methicillin-resistant Staphylococcus aureus in two child care centers [J].
Adcock, PM ;
Pastor, P ;
Medley, F ;
Patterson, JE ;
Murphy, TV .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :577-580
[2]  
Berner B J, 1992, J Am Acad Nurse Pract, V4, P89, DOI 10.1111/j.1745-7599.1992.tb00817.x
[3]   The changing epidemiology of Staphylococcus aureus? [J].
Chambers, HF .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :178-182
[4]   Community-acquired meticillin-resistant Staphylococcus aureus in Australia [J].
Collignon, P ;
Gosbell, I ;
Vickery, A ;
Nimmo, G ;
Stylianopoulos, T ;
Gottlieb, T .
LANCET, 1998, 352 (9122) :145-146
[5]   STAPHYLOCOCCUS-AUREUS LEUKOCIDIN - A NEW VIRULENCE FACTOR IN CUTANEOUS INFECTIONS - AN EPIDEMIOLOGIC AND EXPERIMENTAL-STUDY [J].
CRIBIER, B ;
PREVOST, G ;
COUPPIE, P ;
FINCKBARBANCON, V ;
GROSSHANS, E ;
PIEMONT, Y .
DERMATOLOGY, 1992, 185 (03) :175-180
[6]  
*CTR DIS CONTR, 1981, MMWR-MORBID MORTAL W, V30, P185
[7]  
*CTR DIS CONTR PRE, 1999, MMWR-MORBID MORTAL W, V48, P707
[8]   TREATMENT OF EXPERIMENTAL ENDOCARDITIS DUE TO METHICILLIN-SUSCEPTIBLE OR METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS WITH TRIMETHOPRIM-SULFAMETHOXAZOLE AND ANTIBIOTICS THAT INHIBIT CELL-WALL SYNTHESIS [J].
DEGORGOLAS, M ;
AVILES, P ;
GUERRERO, MLF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :953-957
[9]   Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children [J].
Frank, AL ;
Marcinak, JF ;
Mangat, PD ;
Schreckenberger, PC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (11) :993-1000
[10]   Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors [J].
Gorak, EJ ;
Yamada, SM ;
Brown, JD .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) :797-800